View Older Stories

Jan 12, 2026 08:10AM Arcutis projects ZORYVE sales of $455-470 million for 2026

Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026

Dec 8, 2025 04:03PM Arcutis appoints Amit Munshi to board, founder Bhaskar Chaudhuri retires

Nov 28, 2025 06:33AM Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $37 at Mizuho

Nov 17, 2025 08:04AM FDA accepts Arcutis application to expand ZORYVE cream to children ages 2-5

Nov 4, 2025 08:04AM Arcutis publishes long-term ZORYVE safety data for seborrheic dermatitis

Oct 30, 2025 08:03AM Arcutis launches ZORYVE cream for atopic dermatitis in children ages 2-5

Oct 29, 2025 06:49AM Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $30 at H.C. Wainwright

Oct 29, 2025 06:11AM Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $32 at Mizuho

Oct 28, 2025 04:19PM Arcutis Biotherapeutics, Inc. (ARQT) Tops Q3 EPS by 15c

Oct 28, 2025 08:34AM Arcutis reports 122% quarterly revenue growth for ZORYVE

Oct 24, 2025 08:00AM Arcutis presents new ZORYVE data on sleep quality and long-term control

Oct 7, 2025 04:02AM Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $26 at Mizuho

Sep 3, 2025 11:44AM Arcutis submits application to expand ZORYVE for children ages 2-5

Aug 6, 2025 04:14PM Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 4c

Jul 21, 2025 07:05AM Guggenheim Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT)

Jul 3, 2025 09:29AM Morgan Stanley Assumes Arcutis Biotherapeutics Inc. (ARQT) at Overweight, PT $20

Jun 9, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT)

Jun 3, 2025 06:55AM H.C. Wainwright Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT)

May 22, 2025 02:16PM Arcutis Biotherapeutics (ARQT) ZORYVE Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

May 7, 2025 11:19AM Arcutis Biotherapeutics (ARQT) announces positive data from ZORYVE trial

May 7, 2025 05:09AM Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $20 at Jefferies

May 6, 2025 04:55PM Arcutis Biotherapeutics, Inc. (ARQT) Tops Q1 EPS by 1c

Apr 10, 2025 04:31PM Arcutis Biotherapeutics (ARQT) appoints Latha Vairavan as CFO after Topper retirement

Apr 3, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT)

Apr 2, 2025 01:18PM Arcutis Biotherapeutics (ARQT) and Padagis Agree to Stay Patent Lawsuit

Mar 11, 2025 02:19PM Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $19 at Jefferies

Feb 26, 2025 08:02AM Arcutis Biotherapeutics (ARQT): FDA Accepts sNDA for ZORYVE Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Feb 26, 2025 05:28AM Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $21 at Mizuho

Feb 25, 2025 04:40PM Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 19c

Feb 24, 2025 08:00AM Arcutis Biotherapeutics (ARQT) Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic

Jan 13, 2025 07:17AM Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $20 at Needham

Jan 6, 2025 04:32PM Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $20 at Mizuho, Top Pick

Dec 30, 2024 06:32AM H.C. Wainwright Starts Arcutis Biotherapeutics Inc. (ARQT) at Buy

Dec 16, 2024 08:06AM Arcutis Biotherapeutics (ARQT) Submits ZORYVE Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Dec 3, 2024 08:05AM Arcutis Biotherapeutics (ARQT) Promotions on Executive Management Team

Nov 26, 2024 02:22PM Arcutis Biotherapeutics (ARQT) December 10 puts and December 12.50 calls active as share price up 4.4%

Nov 6, 2024 04:14PM Arcutis Biotherapeutics, Inc. (ARQT) Tops Q3 EPS by 9c

Oct 18, 2024 08:21AM Arcutis Biotherapeutics (ARQT) Announces Health Canada Approval of ZORYVE Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Oct 3, 2024 06:40AM Mizuho Reiterates Outperform Rating on Arcutis Biotherapeutics Inc. (ARQT)

Sep 24, 2024 08:00AM Arcutis Biotherapeutics (ARQT): FDA Accepts NDA Application for ZORYVE Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Sep 19, 2024 08:07AM Arcutis Biotherapeutics (ARQT) Announces Publication of ZORYVE Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in JAMA

Aug 28, 2024 08:00AM Arcutis Biotherapeutics (ARQT) Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile

Aug 28, 2024 02:13AM Jefferies Starts Arcutis Biotherapeutics Inc. (ARQT) at Buy

Aug 16, 2024 02:59PM Mizuho Reiterates Outperform Rating on Arcutis Biotherapeutics Inc. (ARQT)

Aug 15, 2024 09:21AM TD Cowen Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT)

Aug 14, 2024 04:20PM Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 9c

Jul 29, 2024 07:32AM Arcutis Biotherapeutics (ARQT) Launches ZORYVE Cream 0.15% for the Treatment of Atopic Dermatitis

Jul 23, 2024 08:02AM Arcutis Biotherapeutics (ARQT) Submits Supplemental New Drug Application for ZORYVE Foam

Jul 23, 2024 05:54AM Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $19 at Mizuho

View Older Stories